DuPont de Nemours, Inc. · NYSE:DD
DuPont de Nemours — DuPont — Technical Presentation (October 2014)
46 slides from DuPont de Nemours's technical presentation, Oct 2, 2014
Slide 1: The Results Are In — First Industry Summary Report
The Results Are In — First Industry Summary Report October 2, 2014
Slide 2: Presenters
Presenters Bruce A. Yost, Ph.D. Global Technical Director Michael H. Scholla, Ph.D. Global Regulatory Director Leslie Love North America MDM Specialist 2
Slide 3: Today's Bottom Line
Today’s Bottom Line ! Pre- and post-sterilization package results to date continue to indicate functional equivalence ! U.S. FDA affirmation of functional equivalence is expected 3Q 2015 ! Guidance received from regulatory authorities in Japan, China and Canada and from six Notified Bodies in Europe
Slide 4: What You're Going To Hear Today
What You’re Going To Hear Today ! MPTP Package Testing Results — First Complete Summary Report ! Regulatory and Timeline Updates ! Information Available to Help You Be Ready Expect U.S. FDA to affirm functional equivalence 3Q 2015 4
Slide 5: DuPont and Industry Collaborative Cast of Thousands
DuPont and Industry Collaborative Cast of Thousands 5
Slide 6: Publication of MPTP Test Results
Technical Publication of MPTP Test Results Timing 1A—Pre-sterilization and Post-sterilization, t=0, Initial Results May 2014 1B—Pre-sterilization and Post-sterilization, t=0, Final Results TODAY! 2—Accelerated Aging (1, 3 and 5 Years) Real-time Aging (1 Year) PARTIAL TODAY! Additional Accelerated Ag
Slide 7: U.S. FDA Transition Protocol Test Matrix — Nelson Laboratories Testing Status
Technical U.S. FDA Transition Protocol Test Matrix — Nelson Laboratories Testing Status (as of September 10, 2014) 7
Slide 8: Phantom Protocol Test Matrix — Nelson Laboratories Testing Status
Technical Phantom Protocol Test Matrix — Nelson Laboratories Testing Status (as of September 10, 2014) 8
Slide 9: MPTP Data Statistically Analyzed at This Time
Technical MPTP Data Statistically Analyzed at This Time 114,729 Package visual inspections — ASTM F1886M 53,664 Seal strength measurements — ASTM F88 9,522 Package integrity tests — ASTM F1929 1,302 Microbial barrier tests — ASTM F2638 And, still counting! 9
Slide 10: Pre- & Post-Sterilization Visual Inspection Summary — ASTM F1886M
Technical Pre- & Post-Sterilization Visual Inspection Summary — ASTM F1886M 10
Slide 11: Pre- & Post-Sterilization Package Integrity Summary — ASTM F1929
Technical Pre- & Post-Sterilization Package Integrity Summary — ASTM F1929 11
Slide 12: Pre- & Post-Sterilization Microbial Barrier Summary — ASTM F2638
Technical Pre- & Post-Sterilization Microbial Barrier Summary for 1073B and 1059B — ASTM F2638 12
Slide 13: Pass/Fail Summary for Seal Strength — ASTM F88
Technical Industry Summary: MPTP Test Results at Pre- & Post-Sterilization, Pass/Fail Summary for Seal Strength* — ASTM F88 13
Slide 14: Footnotes and Comment on Seal Strength Summary Table
Technical Footnotes and Comment on Pre- & Post-Sterilization Seal Strength Summary Table *Vent bag, Kwikbreathe™ True Header bag and weld seal bag seal strengths are not included; the failure modes were non-peelable seals. **A high sealing condition for one package configuration exceeded the high en
Slide 15: Driver for Root Cause Failure Analysis of Seal Strength Anomaly
Technical Driver for Root Cause Failure Analysis (RCFA) of Seal Strength Anomaly 15
Slide 16: Percent Change in Seal Strength for Maximum Load — ASTM F88
Technical Percent Change in Seal Strength Relative to the Control for Maximum Load — ASTM F88 16
Slide 17: Percent Change in Seal Strength for Average Load — ASTM F88
Technical Percent Change in Seal Strength Relative to the Control for Average Load — ASTM F88 17
Slide 18: Seal Strength Change for Coated and Uncoated 1073B Cells
Technical Percent Change in Seal Strength Relative to the Control for Coated and Uncoated 1073B Cells — ASTM F88 18
Slide 19: Seal Strength Change for Coated 1073B Lids/Rigid Trays
Technical Percent Change in Seal Strength Relative to the Control for Coated 1073B Lids/Rigid Trays — ASTM F88 19
Slide 20: 1-Year Accelerated Aging Package Integrity Summary — ASTM F1929
Technical 1-Year Accelerated Aging Package Integrity Summary for 52 Cells — ASTM F1929 20
Slide 21: 1-Year Accelerated Aging Microbial Barrier Summary — ASTM F2638
Technical 1-Year Accelerated Aging Microbial Barrier Summary for 52 Cells — ASTM F2638 21
Slide 22: 1-Year Accelerated Aging Pass/Fail Summary for Seal Strength
Technical Industry Summary: MPTP 52 Cell Test Results at 1-Year Accelerated Aging, Pass/Fail Summary for Seal Strength — ASTM F88 22
Slide 23: Seal Strength Change, Maximum Load, 1-Year Accelerated Aging
Technical Percent Change in Seal Strength Relative to the Control for Maximum Load at 1-Year Accelerated Aging — ASTM F88 23
Slide 24: Seal Strength Change, Average Load, 1-Year Accelerated Aging
Technical Percent Change in Seal Strength Relative to the Control for Average Load at 1-Year Accelerated Aging — ASTM F88 24
Slide 25: NEW Transition Protocol Material Data
Technical NEW Transition Protocol Material Data ! Effects of sterilization and 3-year accelerated aging on: -- material puncture strength -- material tensile strength -- material microbial barrier (ASTM F2638) ! Effects of sterilization on material microbial barrier (ASTM F1608) 25
Slide 26: Sterilization and Aging Effects on Material Puncture Strength for 1073B
Technical Effects of Sterilization and 1- and 3-Year Accelerated Aging on Material Puncture Strength for 1073B 26
Slide 27: Sterilization and Aging Effects on Material Microbial Barrier for 1073B
Technical Effects of Sterilization and 1- and 3-Year Accelerated Aging on Material Microbial Barrier for 1073B — ASTM F2638 27
Slide 28: Effects of Sterilization on Material Microbial Barrier for 1073B — ASTM F1608
Technical Effects of Sterilization on Material Microbial Barrier for 1073B — ASTM F1608 28
Slide 29: Additional Data Generated Per Industry Requests
Technical Additional Data Generated Per Industry Requests Available on our website: ! Particle generation ! Steam and low-temperature oxidative sterilization behaviors ! Dimensional stability study (steam–freeze–thaw–freeze–thaw) ! DSC, FTIR NEW on our website: ! Dynamic/static coefficient of fricti
Slide 30: Publication of MPTP Test Results
Technical Publication of MPTP Test Results Timing 1A—Pre-sterilization and Post-sterilization, t=0, Initial Results May 2014 1B—Pre-sterilization and Post-sterilization, t=0, Final Results TODAY! 2—Accelerated Aging (1, 3 and 5 Years) Real-time Aging (1 Year) PARTIAL TODAY! Additional Accelerated Ag
Slide 31: Global Members of the DuPont Medical and Pharmaceutical Protection Regulatory Team
Global Members of the DuPont Medical and Pharmaceutical Protection Regulatory Team Michael H. Scholla, Ph.D. Thierry Wagner Ichiro Ikeda Park J. Qian Jane E. Severin, Ph.D., CPP Global Regulatory Director EMEA Regulatory Director Asian Regulatory Director Regulatory Affairs Manager, North America Ch
Slide 32: Regulatory Guidance
Regulatory Regulatory Guidance Documents available on our website: ! Guidance from U.S. FDA -- March 1, 2011 -- October 18, 2012 ! Guidance from Japan -- September 19, 2012 -- September 25, 2013 ! Summary of guidance from China, CFDA-Jinan ! Guidance from Health Canada ! Guidance from European Notif
Slide 33: Regulatory Guidance Letter from DQS Medizinprodukte GmbH
‘egulatory DQS Medizinprodukte GmbH DQsS, | MED To whom it may concer, Frankfurt a. MA 09.09.2014 DuPont Medical and Pharmaceutical Packaging will be transitioning Tyvek® 10738, ‘and 10598 styles for medical packaging applications to manufacturing lines using the latest Tyvek® manufacturing technolo
Slide 34: DuPont Medical and Pharmaceutical Protection — Global MDM Support Team
DuPont Medical and Pharmaceutical Protection — Global MDM Support Team Leslie Love Jose Arevalo Karen Polkinghorne Nicole Kaller Helmut Scheckenbach North America North America and North America EMEA EMEA Central America Eric Schmohl Joong Siong Bong Coy Li Norihiko Matsuda EMEA ASEAN China Japan 34
Slide 35: MPTP Milestones
MPTP Milestones 1 M 2 Developmental Developmental Material Creation Material Testing and Industry Evaluation 7 M 8 MPTP Package Phantom Protocol Creation and Testing Sterilization Regulatory Milestones M Mw U.S. FDA Transition Guidance Received Protocol Reviewed from Six Notified and Accepted by Bod
Slide 36: The Time to Get Ready Is Now
Commercialization The Time to Get Ready Is Now ! What can MDMs do to be ready? • Proceed with your change management process, including risk assessments and associated documentation • Use controlled sales material to complete any additional testing as determined by your own risk assessments • Ensure
Slide 37: Coming Soon — New MPTP Package Test Results Selector Tool
Commercialization Coming Soon — New MPTP Package Test Results Selector Tool 37
Slide 38: Coming Soon — New App for Mobile Devices
Commercialization Coming Soon — New App for Mobile Devices 38
Slide 39: www.areyouready.tyvek.com
Commercialization www.areyouready.tyvek.com What’s New: ! MPTP pre- and post-sterilization package data ! 1-Year accelerated aging package data ! 3-Year accelerated aging material data ! Dynamic/static coefficient of friction data ! Parker (surface) smoothness data ! Surface energy data ! Guidance f
Slide 40: Other Ways to Stay Informed
Commercialization Other Ways to Stay Informed ! www.transition.tyvek.com ! www.areyouready.tyvek.com ! Global webcasts – live or available on-demand for up to a year ! Frequently Asked Questions Document ! Tyvek® Rx eNewsletter ! Face-to-face seminars ! Trade and technical forums ! Individual meetin
Slide 41: Today's Bottom Line
Today’s Bottom Line ! Pre- and post-sterilization package results to date continue to indicate functional equivalence ! U.S. FDA affirmation of functional equivalence is expected 3Q 2015 ! Guidance received from regulatory authorities in Japan, China and Canada and from six Notified Bodies in Europe
Slide 42: Mark Your Calendars
Mark Your Calendars ! DuPont Seminar at Michigan State University—October 9 ! DuPont Seminar in the Dominican Republic—To be rescheduled 1Q 2015 ! Next global webcast—November 13—more interactive discussion on functional equivalence and material interchangeability ! Meet the DuPont team of experts a
Slide 43: A Note of Appreciation
A Note of Appreciation ! Thank you for your business, your continued support and your confidence in DuPont ! We are committed to support you throughout this transition ! Together, we can continue to meet the needs of a growing population for safe and sustainable medical packaging www.transition.tyve
Slide 44: Questions?
Questions? www.transition.tyvek.com www.areyouready.tyvek.com 44
Slide 45: Thank you!
Thank you! Thank you for attending today’s Webcast: The Results Are In — First Industry Summary Report Today’s webcast will be archived for one year for on-demand viewing within this environment. For any additional questions, please contact us: Daphne Allen, Editor, Pharmaceutical & Medical Packagin
Slide 46: Copyright © 2014 DuPont. All rights reserved.
Copyright © 2014 DuPont. All rights reserved. The DuPont Oval Logo, DuPont™ and Tyvek® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates. 46